PROFILBARU.COM

CYB004
Clinical data
Other names	CYB-004; Deuterated dimethyltryptamine; Deuterated DMT; dDMT
Routes of; administration	Inhalation, intravenous
Drug class	Serotonergic psychedelic; Serotonin receptor agonist

CYB004, or CYB-004, also known as deuterated dimethyltryptamine (dDMT), is a serotonergic psychedelic related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder.^[1]^[4]^[2]^[3] It is administered by inhalation or intravenous injection.^[1]^[2]

It is a tryptamine derivative and is a deuterated analogue and form of DMT.^[1]^[4]^[3] The pharmacodynamic profile of CYB004, including its interactions with serotonin receptors and its effects in animals, is similar to that of DMT.^[3] As with DMT, CYB004 is a potent agonist of the serotonin 5-HT_2A receptor and produces psychedelic-like effects in animals.^[1]^[5]^[3] However, CYB004, due to its deuteration, is more resistant to metabolism than DMT and shows a longer elimination half-life (by 2.5- to 2.9-fold) and slower clearance (by 38 to 55%) in animals.^[3] The brain to plasma ratio of CYB004 was also increased (by 30%) relative to DMT, indicating slightly greater central permeability as well.^[3]

As of August 2024, CYB004 is in phase 2 clinical trials for generalized anxiety disorder.^[1]^[4] It was also under development for the treatment of substance-related disorders and of other psychiatric disorders, but development for these indications was discontinued.^[1] The drug is under development by Cybin.^[1]^[4] The exact chemical structure of CYB004 (i.e., which hydrogen atoms are deuterated) does not yet seem to have been disclosed.^[1] However, Cybin patented deuterated tryptamines, including deuterated forms of DMT like DMT-d₁₀, in 2023.^[6] Other related drugs include the deuterated tryptamine CYB003 and the deuterated phenethylamines CYB005 and CYB210010.^[5]^[2]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "CYB 004". AdisInsight. 14 August 2024. Retrieved 28 October 2024.
^ ^a ^b ^c ^d Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nature Biotechnology. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.
^ ^a ^b ^c ^d ^e ^f ^g "ACNP 62nd Annual Meeting: Poster Abstracts P1 - P250". Neuropsychopharmacology. 48 (Suppl 1). Springer Science and Business Media LLC: 63–210. December 2023. doi:10.1038/s41386-023-01755-5. PMC 10729595. PMID 38040809.
^ ^a ^b ^c ^d "Delving into the Latest Updates on Deuterated dtryptamine with Synapse". Synapse. 27 October 2024. Retrieved 28 October 2024.
^ ^a ^b Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, et al. (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". International Journal of Molecular Sciences. 23 (24): 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419.
^ US 2023/0357147, Nivorozhkin A, Palfreyman M, "Deuterated tryptamine derivatives and methods of use", published 8 October 2024, assigned to Cybin IRL Ltd.